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with increased risk of
venous
thromboembolism.
• The association is
strongest for unpro-
voked events.
Several case-control studies have reported elevated plasma von Willebrand factor (VWF)
levels in patients with venous thromboembolism (VTE) compared with controls. However,
because few studies have investigated the association in a prospective design, it is unclear
whether elevated plasma VWF is a risk factor or a consequence of the VTE event. Therefore,
we aimed to investigate the prospective association between plasma VWF levels and risk of
VTE, as well as to perform subgroup analyses of deep vein thrombosis (DVT) and pulmonary
embolism. We established a population-based nested case-control study of 414 VTE cases
and 843 age- and sex-matched controls based on the Tromsø study cohort (1994-2007).
Blood samples were collected at cohort baseline (1994-1995). Odds ratios (ORs) with 95%
confidence intervals (CIs) for VTE were estimated across quartiles of VWF levels. We found
that the risk of VTE increased linearly across quartiles of VWF levels (P for trend 5 .023).
Participants with VWF in the highest quartile had an OR of 1.45 (95% CI, 1.03-2.03) for VTE
compared with those in the lowest quartile. The association was strongest for unprovoked
VTE (OR, 2.74; 95% CI, 1.66-4.54) and unprovoked DVT in particular (OR, 6.73; 95% CI, 3.07-
14.76). Further adjustment for body mass index, C-reactive protein, hypertension, estrogen
use, and smoking had a modest effect on the risk estimates. To conclude, we found a dose-
dependent relationship between plasma VWF levels and future risk of incident VTE, and
unprovoked events in particular. Our findings suggest that VWF may represent a promising
biomarker for future risk of incident VTE.
Introduction
Venous thromboembolism (VTE), a collective term for deep vein thrombosis (DVT) and pulmonary
embolism (PE), is a common disease with important short- and long-term complications, such as
recurrence, postthrombotic syndrome, chronic thromboembolic pulmonary hypertension, and
death.1-6 In contrast to the declining incidence of arterial cardiovascular disease (CVD), a slight
increase in VTE incidence has been observed over the last decades.7-10 This trend is expected to persist
as a result of the increasing prevalence of major VTE risk factors, such as advancing age, cancer, and
obesity.11,12 To reduce the burden of VTE in the population, it is imperative to identify individuals at high
risk and provide targeted prevention. Hence, there is an urgent need to identify novel biomarkers and
increase the understanding of causal pathogenic pathways of VTE.
von Willebrand factor (VWF) is a multimer glycoprotein that is synthesized by endothelial cells and
megakaryocytes. Endothelial cells are the major cellular source of circulating VWF; therefore, VWF is
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regarded as a reliable marker of endothelial cell activation.13
Platelets release a-granules containing VWF when activated,
whereas endothelial cells combine constitutive secretion and
release fromWeibel-Palade bodies upon stimulation.14-16 Thrombin
generation and acute-phase reactions are among the stimuli that
induce release of VWF.17,18 VWF has a dual role in hemostasis: it
promotes adhesion and cohesion of platelets by acting as a ligand
for their glycoproteins and serves as the carrier and protector for
coagulation factor VIII (FVIII).19 Plasma levels of VWF and FVIII are
strongly interrelated, and both are associated with the risk of
VTE.20-23 However, the majority of data on VWF and VTE risk arises
from case-control studies,24-30 which may be susceptible to bias
because of reverse causation and selection of controls. Few
studies have investigated the relationship between VWF and
VTE using a prospective design.21 In the Longitudinal Investiga-
tion of Thromboembolism Etiology (LITE) study, a cohort of 19 231
participants with 159 VTE events, VWF and FVIII were linearly
associated with increased VTE risk.21 To confirm a temporal
relationship between increased levels of VWF and VTE risk, there is
a need for more prospective data from unselected populations.
Insight into the nature of the association may increase our
understanding of the VTE pathophysiology and improve strate-
gies for prevention.
In the present study, we sought to investigate the prospective
association between plasma VWF levels and risk of incident VTE,
including the subtypes DVT and PE, in a nested case-control study
derived from a general population. We hypothesized that individuals
with elevated VWF levels would be at higher risk for VTE.
Methods
Study population
The Tromsø Study is a single-center population-based cohort with
repeated health surveys of the inhabitants of Tromsø, Norway.31
The present nested case-control study is derived from the fourth
survey (Tromsø 4), which was conducted in 1994-1995. All
inhabitants aged $25 years were invited to participate in this
survey; 27 158 individuals (77% of those invited) took part.
Participants were followed from the date of inclusion until an
incident VTE, migration, death, or end of follow-up (1 September
2007). During follow-up, 462 participants experienced a VTE event.
For each case, 2 age- and sex-matched controls were randomly
sampled from the parent cohort, and these had to be alive at the
index date of the corresponding VTE event. Insufficient quality of
plasma samples led to exclusion of 48 cases and 81 controls,
resulting in 414 cases and 843 controls in the final analytical
sample. A flowchart of study participants is depicted in Figure 1. All
participants gave their informed written consent to participate, and
the regional committee for medical and health research ethics
approved the study.
Identification and adjudication of VTE events
All first lifetime VTE events were identified using the hospital
discharge diagnosis registry, the radiology procedure registry, and
the autopsy registry at the University Hospital of North Norway,
which is the only hospital in the study region. Trained personnel
reviewed the medical record of each potential case, and VTE was
only registered when clinical signs and symptoms were combined
with objective radiological confirmation and resulted in a diagnosis
of VTE requiring treatment (unless contraindications were speci-
fied). VTE identification and adjudication have been described in
detail.32 All events were classified as a DVT or PE and as provoked
or unprovoked. In case of simultaneous evidence of DVT and PE,
the event was classified as a PE. An event was classified as
provoked if it occurred in the presence of $1 provoking factor.
Surgery or trauma within 8 weeks prior to the event, an acute
medical condition (myocardial infarction, ischemic stroke, or
infectious disease), active cancer, and marked immobilization
(wheelchair confinement or .3 days bed rest) were regarded as
provoking factors. Other factors, such as venous catheters, were
also recognized as provoking when specifically accentuated by
a physician in the medical record.
Baseline measurements
Baseline information was collected through physical examina-
tions, blood samples, and questionnaires. Height (to the nearest
centimeter) and weight (to the nearest 0.5 kg) were measured with
participants in light clothing and no shoes. Body mass index (BMI)
was calculated as weight in kilograms divided by the square of
height in meters. Specially trained personnel used an automatic





















Figure 1. Flowchart of the study population. The chart
illustrates the nested case-control design. Subjects were sam-
pled from the general population, aged $25 years. Controls were
age- and sex-matched with the cases.
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blood pressure measurements on the upper right arm of all
participants. Participants rested in a sitting position for 2 minutes
before and between the measurements, and the last 2 measure-
ments were used to calculate the mean systolic and diastolic blood
pressure. History of CVD (myocardial infarction, stroke, or angina
pectoris) and cancer, as well as estrogen use and smoking, was
obtained through self-administered questionnaires.
At baseline, nonfasting blood was collected from an antecubital vein
into 5-mL Vacutainers (Becton Dickinson, Le Pont-de-Claix, France)
containing EDTA (K3-EDTA 40 mL, 0.37 mol/L per tube) as an
anticoagulant. Centrifugation at 3000g at room temperature was
done for 10 minutes to prepare platelet-poor plasma. Thereafter, the
supernatant was transferred into cryovials (Greiner Laboratechnik,
Nürtringen, Germany) in 1-mL aliquots and stored at 280°C until
further analysis.
Laboratory analyses
Measurement of VWF and C-reactive protein (CRP) was performed
at the Research Institute of Internal Medicine at Oslo University
Hospital, Rikshospitalet. Plasma samples were thawed in a water
bath for 5 minutes at 37°C before platelet-free plasma was obtained
by centrifugation at 13 500g for 2 minutes. Commercially available
reagents (R&D Systems, Minneapolis, MN) by enzyme immunoas-
say (EIA) in a 384 format were used with a SELMA pipetting robot
(Jena, Germany) and a BioTek (Winooski, VT) dispenser/washer
(EL406) to measure high-sensitivity CRP. Absorption was read at
450 nm using an EIA plate reader (Synergy H1 Hybrid; BioTek) with
a wavelength correction set to 540 nm. The intra- and interassay
coefficients of variation were 2.6% and 9.1%, respectively.
Plasma VWF levels were measured by EIAs with antibodies
(A0082, P02256) obtained from Dako (Glostrup, Denmark)
using a polyclonal antibody for coat (A0082) and a horseradish
peroxidase–conjugated polyclonal antibody for detection (P02256).
Parallel-diluted pooled human plasma from 20 healthy individuals
was used as standard, and the mean value in the control population
was set to 100%. All other values were adjusted accordingly. The
intra- and interassay coefficients of variation were 2.6% and 10.8%,
respectively.
Statistical analyses
Statistical analyses were carried out with STATA version 16.0
(Stata Corporation, College Station, TX) and R version 3.6.3 (The R
Foundation for Statistical Computing, Vienna, Austria).
Participants were categorized according to quartiles of plasma
VWF levels, with cutoffs determined in the control population.
Baseline characteristics according to quartiles of VWF were
expressed as mean (6 standard deviation) or median (25th-75th
percentile) for continuous variables and as percentages (quantity)
for categorical variables.
Unconditional logistic regression was used to estimate odds ratios
(ORs) with 95% confidence intervals (CIs) for VTE according to
quartiles of VWF plasma levels. The lowest quartile was used as the
reference category. We performed analyses for overall VTE and in
subgroups according to VTE location (DVT or PE) and presence of
provoking factors (provoked or unprovoked). The P value for linear
trend of VTE risk was estimated across increasing quartiles of VWF.
The associations were adjusted for age and sex in model 1, with the
addition of BMI in model 2 and the further addition of CRP in
model 3.
VWF is a modifiable risk factor, and a long follow-up (average
follow-up was 7 years) could introduce regression dilution bias
and result in underestimated associations.33 To address this, we
performed logistic regression analyses with restriction of time from
baseline to the VTE event, while keeping all controls in the analyses.
These analyses generated ORs at every 0.1-year increase in time
from baseline and plotted them as a function of this maximum time.
Analyses were set to require $10 VTE events.
Results
The distribution of baseline characteristics across quartiles of
plasma VWF levels is shown in Table 1. The mean age, proportion of
women, and participants with hypertension increased across the
quartiles. In the lowest quartile, history of CVD was less frequent,
whereas smoking was more common compared with the other
quartiles. Mean BMI, median CRP, history of cancer, and daily
estrogen use were similar across VWF quartiles.
Table 1. Distribution of baseline characteristics according to quartiles of plasma levels of VWF
Plasma VWF, %
Quartile 1 (<88.5) Quartile 2 (88.5-94.6) Quartile 3 (94.7-104.7) Quartile 4 (‡104.7)
n 298 305 315 339
Age, y 56.4 6 14.1 58.9 6 14.1 61.3 6 12.8 63.9 6 13.0
Males 49.7 (148) 47.9 (146) 46.7 (147) 44.5 (151)
BMI, kg/m2 25.5 6 3.8 26.8 6 4.5 26.1 6 3.7 27.0 6 4.8
CRP, mg/L 1.29 (0.65-2.35) 1.05 (0.59-1.90) 1.14 (0.65-1.88) 1.36 (0.72-2.36)
Hypertension* 49.8 (148) 55.6 (169) 54.9 (173) 62.2 (211)
Cancer† 4.8 (12) 6.2 (15) 8.1 (20) 4.3 (11)
CVD† 10.1 (30) 17.4 (53) 18.7 (59) 16.8 (57)
Estrogen use‡ 4.4 (13) 4.3 (13) 5.7 (18) 4.7 (16)
Smoking‡ 45.3 (135) 28.2 (86) 23.5 (74) 26.3 (89)
Continuous variables are shown as mean (6 standard deviation) or median (25th-75th percentile). Categorical variables are shown as percentages (n).
*Defined as systolic blood pressure $140 mm Hg or diastolic blood pressure $90 mm Hg.
†Self-reported history of cancer or myocardial infarction, angina, or stroke (CVD) at baseline.
‡Self-reported daily use of oral contraceptives or hormonal replacement therapy (estrogen use) or smoking of cigarettes or cigars (smoking).
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Characteristics of the VTE events are reported in Table 2. Mean age
at the VTE event was 67.56 13.6 years, and the proportion of men
was 48.3%. DVTs constituted 62.6% of all VTE events, and 58.2%
were classified as provoked VTEs.
The ORs for VTE by quartiles of plasma VWF levels are shown in
Table 3. For overall VTE, the ORs increased across quartiles of
VWF in the age- and sex-adjusted model (model 1: P for trend 5
.023). Subjects with plasma VWF levels in the highest quartile had
a 1.5-fold higher OR for VTE (OR, 1.45; 95% CI, 1.03-2.03)
compared with subjects with plasma VWF levels in the lowest
quartile. Further adjustment for BMI and CRP (model 2) and
hypertension, estrogen use, and smoking (model 3) attenuated the
ORs only slightly.
Subgroup analyses revealed that elevated plasma levels of VWF
were associated with an increased risk for unprovoked VTE
(Table 3) and DVT (Table 4), whereas no association was observed
for provoked VTE and PE. Compared with the lowest quartile,
plasma VWF levels in the highest quartile yielded age- and
sex-adjusted ORs of 2.74 (95% CI, 1.66-4.54; P for trend ,
.001) for unprovoked VTE, 1.63 (95% CI, 1.09-2.43; P for trend
5 .011) for DVT, and 6.73 (95% CI, 3.07-14.76; P for trend ,
.001) for unprovoked DVT. Similar to overall VTE, additional
adjustment for BMI, CRP, hypertension, estrogen use, and
smoking did not influence the risk estimates substantially.
To assess whether the risk estimates were subjected to regression
dilution bias, we estimated ORs for VTE in those with high (quartile
4) vs low (quartile 1) plasma VWF as a function of time between
baseline blood sampling and the VTE events. As depicted in
Figure 2, the association between plasma levels of VWF and VTE
risk was not substantially diluted during follow-up.
Discussion
In this population-based nested case-control study, we observed
a dose-dependent association between plasma levels of VWF and
future risk of incident VTE. Participants in the highest quartile had
a 1.5-fold higher OR for VTE than did those in the lowest quartile
after adjustment for age and sex. The association was strongest for
unprovoked DVT, with an OR of 6.7 in the highest quartile. The risk
estimates were only slightly attenuated after adjustment for BMI, CRP,
hypertension, estrogen use, and smoking. Analyses with restricted
follow-up time showed that the association remained throughout the
13-year study period. Our findings suggest that VWF may serve as
a biomarker to predict first lifetime VTE and implies a role for early
platelet and endothelial cell activation in the pathogenesis of VTE.
The association between VWF and VTE risk was first recognized in
1995, when Koster and colleagues reported a higher OR for DVT
among participants with elevated levels of VWF in the Leiden
Thrombophilia case-control study.28 The association was replicated
Table 2. Characteristics of VTE events (n 5 414)
Characteristics Data




Unprovoked VTE 41.8 (173)
Provoked VTE 58.2 (241)
Unless otherwise noted, data are % (n).
*Mean 6 standard deviation.
Table 3. ORs with 95% CIs for overall VTE and subgroups according to quartiles of VWF plasma levels
VTE subgroup Controls (n 5 843) Cases Model 1 Model 2 Model 3
Overall VTE n 5 414
VWF Q1 210 88 Ref. Ref. Ref.
VWF Q2 211 94 1.07 (0.75-1.51) 1.03 (0.72-1.46) 1.03 (0.72-1.48)
VWF Q3 210 105 1.20 (0.85-1.70) 1.20 (0.85-1.69) 1.20 (0.84-1.71)
VWF Q4 212 127 1.45 (1.03-2.03) 1.35 (0.96-1.90) 1.36 (0.96-1.92)
P value for trend .02 .05 .05
Provoked VTE n 5 241
VWF Q1 210 62 Ref. Ref. Ref.
VWF Q2 211 56 0.89 (0.59-1.34) 0.86 (0.56-1.30) 0.87 (0.57-1.33)
VWF Q3 210 62 0.97 (0.65-1.46) 0.96 (0.64-1.45) 0.98 (0.65-1.49)
VWF Q4 212 61 0.94 (0.62-1.41) 0.88 (0.58-1.34) 0.90 (0.59-1.37)
P value for trend .9 .7 .8
Unprovoked VTE n 5 173
VWF Q1 210 26 Ref. Ref. Ref.
VWF Q2 211 38 1.50 (0.88-2.57) 1.49 (0.86-2.57) 1.46 (0.84-2.52)
VWF Q3 210 43 1.75 (1.03-2.97) 1.78 (1.04-3.03) 1.72 (1.00-2.94)
VWF Q4 212 66 2.74 (1.66-4.54) 2.59 (1.55-4.32) 2.52 (1.51-4.22)
P value for trend ,.001 ,.001 ,.001
Model 1: adjusted for age and sex. Model 2: model 1 1 BMI and CRP. Model 3: model 2 1 smoking, hypertension, and estrogen use.
Q, quartile; Ref., reference.
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in several case-control studies,24,26,27,29,34 most recently in the
MEGA study, in which a dose-dependent relationship was also
demonstrated at extreme plasma levels of VWF.30 On a general
basis, case-control studies have the important drawback that
plasma samples are collected after the VTE event. Although
data from the MEGA study suggested that plasma VWF levels
remain stable after the initial treatment period,30 it is still
debated whether these VWF levels reflect a higher risk for VTE
or merely a consequence of the acute event itself.28,30 Few
prospective studies have investigated the association between
VWF and VTE risk. In the LITE study, a dose-dependent relationship
between plasma VWF levels and future risk of VTE was observed in
middle-aged participants (age 45-64 years at baseline) from the
Atherosclerosis Risk in the Community cohort across 8 years of
follow-up, whereas results from the Cardiovascular Health Study
cohort with older individuals (age . 65 years at baseline) were
inconclusive.21 Although there were few events (n 5 65) in the
Cardiovascular Health Study, it may be speculated that elevated
VWF levels better reflect VTE risk in the younger population. Notably,
the association between VWF and VTE risk in the Atherosclerosis
Risk in the Community also remained after 13 years of follow-up.35 In
a prospective nested case-control study from the Women’s Health
Table 4. ORs with 95% CIs for overall, provoked, and unprovoked DVT and PE, according to quartiles of plasma VWF level
VTE subgroup Controls (n 5 843) Cases Model 1 Model 2 Model 3
Overall DVT n 5 259
VWF Q1 210 53 Ref. Ref. Ref.
VWF Q2 211 57 1.08 (0.71-1.65) 1.07 (0.70-1.64) 1.06 (0.69-1.63)
VWF Q3 210 65 1.26 (0.83-1.90) 1.26 (0.83-1.90) 1.23 (0.81-1.87)
VWF Q4 212 84 1.63 (1.09-2.43) 1.52 (1.01-2.29) 1.49 (0.99-2.25)
P value for trend 0.01 0.03 0.04
Provoked DVT n 5 156
VWF Q1 210 45 Ref. Ref. Ref.
VWF Q2 211 36 0.79 (0.49-1.27) 0.78 (0.48-1.27) 0.78 (0.48-1.27)
VWF Q3 210 38 0.82 (0.51-1.33) 0.83 (0.51-1.33) 0.83 (0.51-1.34)
VWF Q4 212 37 0.78 (0-48-1.28) 0.74 (0.45-1.21) 0.74 (0.45-1.22)
P value for trend .4 .3 .3
Unprovoked DVT n 5 103
VWF Q1 210 8 Ref. Ref. Ref.
VWF Q2 211 21 2.73 (1.18-6.33) 2.78 (1.19-6.47) 2.73 (1.17-6.40)
VWF Q3 210 27 3.74 (1.65-8.47) 3.79 (1.66-8.62) 3.59 (1.57-8.23)
VWF Q4 212 47 6.73 (3.07-14.76) 6.40 (2.90-14.12) 6.18 (2.78-13.70)
P value for trend ,.001 ,.001 ,.001
Overall PE n 5 155
VWF Q1 210 35 Ref. Ref. Ref.
VWF Q2 211 37 1.04 (0.63-1.72) 0.96 (0.58-1.61) 0.99 (0.59-1.67)
VWF Q3 210 40 1.12 (0.68-1.84) 1.10 (0.67-1.83) 1.15 (0.69-1.92)
VWF Q4 212 43 1.18 (0.72-1.93) 1.11 (0.67-1.84) 1.14 (0.69-1.91)
P value for trend .5 .6 .5
Provoked PE n 5 85
VWF Q1 210 17 Ref. Ref. Ref.
VWF Q2 211 20 1.15 (0.59-2.27) 1.05 (0.53-2.10) 1.14 (0.56-2.31)
VWF Q3 210 24 1.36 (0.70-2.63) 1.32 (0.68-2.56) 1.43 (0.72-2.83)
VWF Q4 212 24 1.33 (0.69-2.57) 1.24 (0.63-2.42) 1.33 (0.67-2.64)
P value for trend .4 .4 .3
Unprovoked PE n 5 70
VWF Q1 210 18 Ref. Ref. Ref.
VWF Q2 211 17 0.94 (0.47-1.88) 0.90 (0.44-1.83) 0.88 (0.43-1.80)
VWF Q3 210 16 0.89 (0.44-1.80) 0.89 (0.43-1.82) 0.89 (0.43-1.84)
VWF Q4 212 19 1.04 (0.52-2.08) 0.98 (0.49-1.98) 0.97 (0.48-1.96)
P value for trend .9 .9 .9
Model 1: adjusted for age and sex. Model 2: model 1 1 BMI and CRP. Model 3: model 2 1 smoking, hypertension, and estrogen use.




 http://ashpublications.org/bloodadvances/article-pdf/5/1/224/1796732/advancesadv2020003135.pdf by guest on 13 O
ctober 2021
Initiative trials, an association with VTE was observed when VWFwas
modeled continuously but not when it was dichotomized at the 75th
percentile.36 In the present study, we add important prospective
evidence on the association between plasma VWF and the risk of
incident VTE in men and women of a wider age range and extend
previous knowledge by showing that the association appears to be
mainly driven by unprovoked events and DVT in particular.
Although plasma levels of VWF are influenced by environmental
factors, it is estimated that genetic variation accounts for up to 65%
of the interindividual variability.37 Genome-wide association studies
have shown that VWF levels are regulated by several genetic
loci; 19 loci have been identified so far.38,39 In recent years, VWF
has been explored as a causal risk factor for VTE. Mendelian
randomization analyses of a recent INVENT consortium meta-
analysis of genome-wide association study results from 46354
individuals reported that a 1 standard deviation increase in
genetically predicted VWF levels was associated with a 2.4-
fold increased OR for VTE, supporting a causal association.38,40 At
the individual level, plasma VWF levels are highly modifiable and
influenced by several factors, such as menstrual cycle, pregnancy,
exercise, aging, circadian rhythm, cigarette smoke, and air
pollution.37 Because of the fluctuating nature of VWF, pro-
spective studies with a long follow-up period may be subject to
regression dilution and underestimation of the true associa-
tion.33 However, in the present study we found that the
association between plasma VWF levels and VTE risk persisted
throughout the entire follow-up period (average duration was
7.1 years). Interestingly, the Women’s Health Initiative study
found that a larger 1-year increase in VWF levels was not
associated with VTE risk.36 This may imply that basal plasma
levels, rather than short-term fluctuations in plasma levels,
of VWF (eg, due to acute-phase reactions) are important for
the VTE risk. Taken together, this underscores that VWF is
a reliable biomarker and suggests that genetic predisposition
likely outweighs the modification through environmental and
acquired factors. Notably, recent findings imply that VWF may
represent a promising therapeutic target,13,41 as well as a biomarker
that may be part of a comprehensive risk-assessment model.
VWF is an unspecific biomarker, and elevated levels indicate platelet
activation and, in particular, endothelial cell activation.13 In recent years,
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Figure 2. Plots of estimated ORs for overall, provoked, and unprovoked VTE and unprovoked deep vein thrombosis as a function of time from baseline (1994-
1995) to VTE events. Participants with plasma VWF levels in the highest quartile were compared with those with levels in the lowest quartile (Q4 vs Q1). Analyses were adjusted
for age and sex. Filled symbols indicate ORs with P , .05. Number of VTE events according to time of follow-up are provided above the plots. Max, maximum; T4, Tromsø 4 survey.
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VWF has been recognized as a risk factor for several conditions,
in the presence and absence of inflammation.42-45 Although the
role of VWF in hemostasis is well described, its etiological role in
thrombogenesis remains to be fully understood. In their case-
control study, Koster and colleagues reported that the univariate
association between VWF and VTE risk disappeared after
adjustment for FVIII.28 On this basis, it was concluded that the
association between VWF and VTE probably is biologically
mediated through increased FVIII levels.28 Currently, no locus
has been identified to influence VWF levels independent of FVIII;
therefore, this hypothesis could not be tested in a Mendelian
randomization design.38 Because circulating FVIII is primarily
determined by VWF, FVIII and VWF have been proposed as
reasonable targets for prevention and treatment of VTE.41 On the
contrary, the VWF-platelet interaction has been suggested to be
of importance primarily in arterial thromboses, and there are
ongoing trials investigating the effect of selective VWF antag-
onists on coronary artery disease and stroke.46 Interestingly,
mouse studies have recently suggested a critical role for VWF in
venous thrombus formation also in the absence of FVIII,47
suggesting that VWF may represent a promising therapeutic
target also in venous thrombosis.13
In subgroup analyses, we observed that VWF was primarily
associated with the risk of DVT and unprovoked VTE events.
Higher levels of FVIII have been observed in patients with
unprovoked VTE,34 and elevated FVIII levels were more prevalent
in patients with DVT compared with PE.48 However, we are not
aware of any previous studies investigating VWF and VTE risk
according to these subgroups. The association with unprovoked
events suggests that elevated plasma VWF levels relate to VTE risk
in the absence of known provoking factors, which may strengthen
the interpretation of a causal association.49 Although PE and DVT
are regarded as 2 entities of the same disease, there are several
examples of risk factors with a differential impact on the presenting
location of VTE.50 Of these, the most prominent is the factor V
Leiden (FVL) paradox; the FVL mutation increases the risk of DVT
but not PE.51 A proposed mechanism hypothesized from experi-
ments in mice is that FVL is associated with enhanced thrombin
generation, resulting in larger and more stable thrombi that are less
prone to embolization.51,52 This hypothesis may also pertain to
VWF, because individuals with elevated plasma VWF levels are
likely to have a higher endogenous thrombin potential because of
the concomitantly elevated FVIII levels.53 Another potential mech-
anism is that elevated VWF levels facilitate more stable thrombi
through the adhesion to integrin aIIbb3 on activated platelets,54
resulting in a tighter anchorage of the platelets to each other and to
the endothelial wall.13
The strengths of this study include the nested case-control design
with a large sample of VTE patients and age- and sex-matched
controls recruited from the same population-based cohort. The
prospective design provided the possibility to gain insight into the
temporal sequence between VWF and VTE risk. Because there is
only 1 hospital in the study area providing VTE diagnostics and
treatment, it is likely that a negligible amount of VTE cases were
missed. This study also has some limitations that need mentioning.
The vast majority of study participants were white; therefore, we
encourage caution when extrapolating these findings to other
ethnicities. Blood samples were drawn in 1994-1995 and stored for
.20 years. This long storage time may have affected the plasma
VWF levels, but it is likely that such an effect would be similar in
cases and controls and not influence the relative differences
between them. Moreover, because the intraindividual plasma VWF
levels may have changed during the long follow-up (mean 7.1
years), a single baseline measurement of VWF at baseline could
yield results subjected to regression dilution bias and under-
estimated associations. However, we did not observe evidence of
regression dilution in our analyses, and the ORs for VTE according
to quartiles of plasma VWF levels remained significant throughout
the entire study period.
In conclusion, we found that higher plasma levels of VWF were
associated with increased risks of incident VTE. The association
was particularly strong for unprovoked DVT, and the increased VTE
risk remained throughout the study period. Our findings suggest
that VWF may serve as a reliable biomarker for future risk of VTE.
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